Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH

doi:10.1200/jco.2012.42.2964

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Identifier:nobleid.org/w1/20260526/FADC42CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FADC42CF.svg?ark=w1%2F20260526%2FFADC42CF)](https://nobleid.org/work/w1/20260526/FADC42CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Identifier:nobleid.org/w1/20260526/FADC42CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FADC42CF.svg?ark=w1%2F20260526%2FFADC42CF)](https://nobleid.org/work/w1/20260526/FADC42CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work